Outcome of Nephrectomies in Malta since 2000
|
|
- Charity Carr
- 5 years ago
- Views:
Transcription
1 Outcome of Nephrectomies in Malta since 2000 Gerald Busuttil, Simon Bugeja, Patrick Zammit, Stephen Mattocks, Karl German Abstract Aim: To audit the oncological results and perioperative surgical outcome of nephrectomies performed in Malta since year Method: A retrospective index case list of all nephrectomies carried out by three urological surgeons at St Luke s and Mater Dei Hospitals from 1 st September 2000 to 31 st March 2012 was compiled from departmental data. Clinical, radiological and histological data were compiled from the case notes and hospital intranet computerised investigation results. Clinical staging of all patients was revised using the Union Internationale Contre le Cancer TNM staging All the patients who underwent nephrectomy for clear cell renal cell carcinoma were stratified according to individual predicted prognosis based on the SSIGN score developed by the Mayo clinic. Results: Between September 2000 and March 2012, 319 nephrectomies were carried out at the Urology Unit, of these 288 were carried out for malignancy, 218 of which were clear cell renal cell carcinoma (RCC). 112 complications were recorded for the whole cohort; two patients died from perioperative complications. 80 patients passed away, 51 of these as a direct consequence of their renal cell cancer. Median duration of follow up was 42.7 months. A Cox model reveals that a SSIGN score greater than 6 significantly worsens survival rate for RCC (p<<0.001). Conclusion: Morbidity following surgery, mortality rates, and oncological results in our single centre study are acceptable when compared to larger series. Gerald Busuttil MRCS(Ed), FEBU* Urology Unit, Department of Surgery Mater Dei Hospital Msida, Malta gerald.busuttil@gov.mt Simon Bugeja MRCS(Ed), FEBU Patrick Zammit FRCS(Ed), FEBU Stephen Mattocks FRCS(Urol), FEBU Karl German MS, FRCS(Urol) *Corresponding Author Keywords Nephrectomy, Renal Cancer, Cancer Specific Survival, Crude Survival, Morbidity Introduction Despite the progress made in recent decades with the elucidation of various molecular pathways involved in the carcinogenesis of renal cell carcinoma of the kidney 1-4 which has paved the way for the development and introduction of systemic targeted therapies, the treatment of renal cell cancer remains predominantly surgical, with a paucity of alternative or adjunctive oncological options available to patients suffering from this aggressive disease. The indication for surgical treatment has also widened with the consolidation of cytoreductive nephrectomy in metastatic disease 5-6 and establishment of laparoscopic techniques outside of centres of excellence. 7-8 Nephrectomy is also sometimes indicated in severe benign diseases of the kidney making it a commonly performed operation in most urological units worldwide. Cancer of the kidney and ureter was seventh most commonly diagnosed cancer in Maltese males in 2012 with an age standardised incidence of 15.0/100,000 9 and represents a significant proportion of the patients seen at our institution s Urology Unit. The increasing use of cross sectional imaging for investigation of various medical complaints has also resulted in an increasing incidence of incidental asymptomatic renal tumours, a phenomenon common to most urology units in the developed world. 10 Method A retrospective index case list of all nephrectomies carried out by three urological surgeons at St Luke s and Mater Dei Hospitals from 1 st September 2000 to 31 st March 2012 was compiled from departmental data. Operative data relating to procedures carried out within our Urology Unit is compiled in a prospective manner using a Microsoft Access -based database, allowing accurate and reliable retrieval of the index case list. Clinical presentation, prognostic factors, histology, radiological characteristics, surgical technique, postoperative morbidity and mortality, length of hospital stay and vital status were compiled from the case notes and hospital intranet radiological and clinical databases. 9
2 Survival data was corroborated with death certificates obtained from the Department of Health Information. Staging of all patients was revised using the TNM staging Union Internationale Contre le Cancer TNM staging 2009, which has been externally validated in ,12 Information from preoperative CT scans and histopathological report of the resected specimen were combined to restage all the patients in the cohort. All the patients who underwent nephrectomy for clear cell renal cell carcinoma were stratified according to individual prognosis based on the Stage, Size, Grade, Necrosis Score Algorithm (SSIGN) developed by the Mayo clinic 13 and recently externally validated in a European study. 15 As the SSIGN score is validated for use only in clear cell renal cell carcinoma, patients whose pathology was not clear cell renal cell carcinoma were excluded from survival analysis, although these records were included in other analyses. 35 patients who developed a second malignancy (excluding squamous cell carcinoma or basal cell carcinoma of the skin) during the study period were excluded from this analysis. Results Patient and tumour characteristics are shown in Table patients underwent nephrectomy between September 2000 and March patients underwent nephrectomy for tumour, of these tumours 218 were clear cell renal cell carcinomas. Other indications for nephrectomy included inflammatory or infective pathologies (26), benign masses (36), polycystic kidney disease (4) and vesico-ureteral reflux with dysplastic kidney (1). 75% (n=241) of the patient cohort were diabetic, other risk factors for renal malignancy included current smoking at time of surgery (16.9%, n=54), smoking history (14.4%, n=46) and positive family history (1.5%, n=5). The local incidence of incidentally detected kidney tumours has been rising over the last decade (35%, n=115) (Figure 1). The total number of nephrectomies performed per year has also been increasing in parallel over the study period. Loin pain was the presenting symptom in 24% (n=82), gross haematuria in 23% (n=79), pyrexia of unknown origin in 3% (n=11), anaemia in 2% (n=8) and abdominal mass in another 2% (n=6). 11 patients (3%) presented with uncommon symptoms, such as nasal congestion from posterior nasal space metastasis, visual deterioration from occipital lobe metastasis and skull metastasis. Information on clinical presentation is not available in 26 patients (8%). The majority of the patients underwent open radical nephrectomy (70%), followed by open partial nephrectomy (Table 1). One patient underwent joint procedure with cardiothoracic surgeons with radical nephrectomy, inferior vena cava exploration and removal of right atrial tumour thrombus under cardio-pulmonary bypass. Table 1: Patient and Tumour Characteristics Total number of patients 319 Nephrectomy for tumour 288 Males (%) 191 (60) Females (%) 128 (40) Age (years) mean (range) ± SD 58.7 (22-90) Radiological Size (cm) mean (range) 6.3 (1-20) Tumour location Upper pole 92 Central 90 Lower pole 77 Complete renal infiltration 10 Renal pelvis 11 Ureter 4 Not available 4 TNM Distribution Localised at presentation T1a N0 M0 71 T1b N0 M0 51 T2a N0 M0 15 T2b N0 M0 19 T3a N0 M0 29 T3b N0 M0 7 T3c N0 M0 2 T4 N0 M0 0 Metastatic at presentation T2a N1 M0 1 T3a N1 M0 1 T3b N1 M0 1 T4 N1 M0 1 T1b N0 M1 1 T2b N0 M1 4 T3a N0 M1 4 T3b N0 M1 1 T3a N1 M1 1 T3b N1 M1 1 T3c N1 M1 2 T4 N1 M1 1 Surgical Procedure Open Radical Nephrectomy 225 Open Partial Nephrectomy 34 Nephroureterectomy 15 Simple Nephrectomy 15 Laparoscopic Partial 13 No Data 11 Laparoscopic Radical 5 Open Radical and Sternotomy 1 Fuhrman grade (mean)
3 Figure 1: Incidence of incidental tumours and total nephrectomy surgeries over study period Table 2: Summary of Complications Haematological Renal/urological Transfusion 28 Temporary Dialysis 8 DVT 2 Febrile reaction to transfusion 1 DIC 1 Perinephric/retroperitoneal haematoma 3 Permanent dialysis (anephric) 2 Renal dysfunction - no dialysis 1 UTI 1 Respiratory Clot colic with obstruction 1 Morbidity and mortality data are shown in Table 2. A total of 62 patients (20%) suffered from a postoperative complication. 46 patients suffered one complication, 12 patients suffered two events and four patients suffered three complications. After excluding post-operative transfusion (9.7%), important complications included pneumonia (15 patients), deterioration in renal function requiring temporary dialysis (8 patients), wound complications (16 patients) and intestinal obstruction requiring laparotomy (3 patients). Two patients were rendered anephric by surgery in the context of adult polycystic kidney disease, and the need for permanent dialysis was determined by pre-existing end-stage renal failure. Two patients died within 30 days of surgery from complications related to the nephrectomy, one patient sustained a myocardial infarct followed by cardiac arrest and a second patient developed DIC after severe haemorrhage and multiple blood transfusions. Oncological results are shown in Table patients who had histologically proven renal cancer were included for analysis of oncological outcome. Patients whose final histological diagnosis was clear cell renal cancer (n=218) were stratified and analysed according to the SSIGN score. This scoring system is based on the pathological tumour stage, tumour size, tumour necrosis, nodal status and presence of distant metastasis. Every patient with known clear cell renal cell carcinoma was included in one of five risk groups. Crude survival and cancer specific survival for each group was calculated and showed using the Kaplan Meier method. (Figures 2 and 3). The same cohort of patients was then divided into two risk groups using a cut off of SSIGN score 6, with the group having a score of > 6 having a statistically significant survival disadvantage (p<0.001). (Figures 4 and 5). Pneumonia 15 Calculous obstruction single kidney 1 Intraoperative desaturation 1 Urocutaneous fistula 1 Pleural effusion 1 Cardiovascular Drug related MI/cardiac arrest 1 Opiate overdose 3 Arrhythmia (cardioversion) 1 Drug rash 1 Arrhythmia (pharmacological rx) 2 Angina 2 Cerebrovascular event 1 GIT/Intrabdominal Hand and Foot Syndrome (TKIs) 1 Body Wall Bowel obstruction (conservative) 3 Wound infection 7 Bowel obstruction (laparotomy) 3 Incisional hernia 7 GI bleed 2 Wound haematoma 2 Psoas abscess (surgical drainage) 1 Systemic Perioperative death Sepsis 3 DIC 1 Hyperglycaemia 2 MI 1 Acute confusion 1 11
4 Table 3: Follow up data Follow up (days) mean (range) 1282 ( ) Figure 2: 10 year crude survival stratified per SSIGN groups A E Adjuvant Oncological Treatment Systemic chemotherapy 8 External beam radiotherapy 15 Interferon 2 Tyrosine kinase inhibitor 7 Local Recurrence n (%) 10 (3.4) Distant Metastasis n (%) 43 (14.9) Metastasis free survival (metastatic pts only) (days) mean (range) 566 (8-3186) Local recurrence free survival (recurring pts only) (days) mean (range) 280 ( ) Metastasis sites n of pts, (%) Lung 21 (30) Bone 12 (17) Liver 9 (13) Retroperitoneal LNs 7 (10) Figure 3: 10 year cancer specific survival stratified per SSIGN groups Adrenal 6 (8) Brain 3 (4) Pancreas 2 (3) Other 11 (15) Second Primary Tumours n of pts, (%) 35, (12%) Site of second primaries, n of pts Bladder 8 Prostate 6 Colon 6 Breast 5 Lung 3 Other 7 12
5 Original Article Figure 4: 10 year crude survival stratified per low/ high risk groups disease and had cytoreductive or palliative nephrectomy to alleviate symptoms. These metastatic patients were not included in the series by Frank et al 13 or Zigeuner et al 14 and this may explain the differences in outcomes observed. In our series the SSIGN score was confirmed to be a good indicator of predicted survival in clear cell carcinoma patients undergoing radical or partial nephrectomy. Table 4: 10 year Cancer Specific Survival stratified by SSIGN score groups SSIGN Score (0-16) Figure 5: 10 year cancer specific survival stratified per low/ high risk groups Discussion In this series, nephrectomy resulted in acceptable morbidity rates. The post-operative 30 day surgical mortality rate of 0.62 % compares well with published figures ranging from 0.77 to 2.3%. 16 Post-operative complication rates are also in line with other published series with a total morbidity rate of 20% (with studies quoting complication rates between 2 and 35%). 17, 18 Oncological results in the clear cell carcinoma group also compare favourably with larger series published by tertiary high volume centres (Table 4). Our results in the very poor prognosis group are significantly worse, however these patients were mostly (19 out of 20) patients who presented with metastatic Malta Medical Journal Volume 26 Issue Number of pts per group (Local Series) Local Series (n = 201) 95% 96% 56% 23% 0% (Mayo Clinic) Frank I et al 10 yr survival (n = 1801) 97% 78% 57% 30% 19% Zigeuner et al - 10 yr survival (n = 2333) 93% 72% 46% 22% 5% This series also outlines local trends in kidney cancer surgery, with partial nephrectomy slowly taking over radical nephrectomy as the technique of choice, 19, 20 in accordance with European Association of Urology guidelines.21 Partial nephrectomy, although being a complex and challenging procedure, affords preservation of renal function which translates lower long term cardiovascular mortality and better overall survival, compared to radical nephrectomy The introduction of laparoscopic techniques into local practice over the last few years is also translating in lower patient morbidity. Our study has some limitations and numerous strong points. Being the only urology unit in the country, follow up is mostly complete with no patients lost to follow up because of migration. Duration of follow ups is adequate with 10 year survival being presented rather than the traditional 5 year survival rates. Patients readmitted with post-operative complications are cared for by the same unit, so recording morbidity is an easier task. Mortality data was corroborated by death certification data obtained from the National Cancer Registry to minimise inaccuracy. Limitations include those inherent to a retrospective audit, including incomplete data, reliance on potentially inaccurate medical notes and bias. Recorded complications were not graded according to a validated severity score because of scant clinical details which precluded accurate stratification. The performance status, co-morbidity and ASA score were not recorded, factors which would be expected to influence postoperative complications rates. 13
6 Data regarding BMI and blood pressure were not recorded, both obesity and hypertension now being considered as risk factors for kidney cancer carcinogenesis. The issue of obesity and metabolic syndrome could have significant local importance, as shown by the high incidence of diabetics in our cohort. Lastly, cancer specific survival rather than overall survival was considered as the hard oncological end point, whilst overall survival might represent oncological outcomes in a more clinically meaningful way. Conclusion Surgical morbidity and mortality rates and oncological results in our single centre study compare well to larger series. Over the study period changes in international guidelines and progress in surgical techniques have been adapted to our local practice with good effect. References 1. Brugarolas J. Renal-Cell Carcinoma Molecular Pathways and Therapies. N Engl J Med Jan 11;356(2): Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, Prognosis, and Targeted Therapy for Renal Cell Carcinoma Exploiting the Hypoxia-Induced Pathway. Clin Cancer Res Oct 15;9(13): Posadas EM, Limvorasak S, Sharma S, Figlin RA. Targeting angiogenesis in renal cell carcinoma. Expert Opin Pharmacother Nov;14(16): Keefe SM, Nathanson KL, Rathmell WK. The molecular biology of renal cell carcinoma. Semin Oncol Aug;40(4): Aizer AA, Urun Y, McKay RR, Kibel AS, Nguyen PL, Choueiri TK. Cytoreductive nephrectomy in patients with metastatic non-clear cell renal cell carcinoma. BJU Int Sep 5; 6. Conti SL, Thomas I-C, Hagedorn JC, Chung BI, Chertow GM, Wagner TH, et al. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer J Int Cancer Oct 17; 7. Zheng J, Zhang X, Geng J, Guo C, Zhang X, Che J, et al. Longterm oncologic outcomes of laparoscopic versus open partial nephrectomy. Chin Med J (Engl). 2013;126(15): Marszalek M, Meixl H, Polajnar M, Rauchenwald M, Jeschke K, Madersbacher S. Laparoscopic and open partial nephrectomy: a matched-pair comparison of 200 patients. Eur Urol May;55(5): Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in Eur J Cancer Apr;49(6): Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma age and stage characterization and clinical implications: study of 1092 patients ( ). Urology Jul;56(1): Lee C, You D, Park J, Jeong IG, Song C, Hong JH, et al. Validation of the 2009 TNM Classification for Renal Cell Carcinoma: Comparison with the 2002 TNM Classification by Concordance Index. Korean J Urol Aug;52(8): Moch H, Artibani W, Delahunt B, Ficarra V, Knuechel R, Montorsi F, et al. Reassessing the Current UICC/AJCC TNM Staging for Renal Cell Carcinoma. Eur Urol Oct;56(4): Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zinche H. An Outcome Prediction Model for Patients with Clear Cell Renal Cell Carcinoma Treated with Radical Nephrectomy Based on Tumor Stage, Size, Grade and Necrosis: The Ssign Score. J Urol Dec;168(6): Zigeuner R, Hutterer G, Chrometcki T, Immamovic A, Kampel-Kettner A, Rehak P, Langner C, K. External Validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score for clear cell carcinoma in a Single European Centre Applying Routine Pathology. European Urology 2010 Jan: 57(1): Ficarra V, Martignoni G, Lohse C, Novara G, Pea M, Cavalleri S, et al. External Validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) Score to Predict Cancer Specific Survival Using a European Series of Conventional Renal Cell Carcinoma. J Urol Apr;175(4): Finlayson EA, Goodney PP, Birkmeyer JD. Hospital volume and operative mortality in cancer surgery: A national study. Arch Surg Jul 1;138(7): Pomara G, Campo G, Francesca F. Intraoperative and postoperative complications of nephron sparing surgery: prevention and possible treatments. Arch Ital Urol Androl Organo Uff Soc Ital Ecogr Urol E Nefrol Assoc Ric Urol Jun;81(2): Patard J-J, Pantuck AJ, Crepel M, Lam JS, Bellec L, Albouy B, et al. Morbidity and Clinical Outcome of Nephron-Sparing Surgery in Relation to Tumour Size and Indication. Eur Urol Jul;52(1): Nieder AM, Taneja SS. The role of partial nephrectomy for renal cell carcinoma in contemporary practice. Urol Clin North Am Aug;30(3): Touijer K, Jacqmin D, Kavoussi LR, Montorsi F, Patard JJ, Rogers CG, et al. The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. Eur Urol Feb;57(2): Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol Sep;58(3): Choi YS, Park YH, Kim Y-J, Kang SH, Byun S-S, Hong S-H. Predictive factors for the development of chronic renal insufficiency after renal surgery: a multicenter study. Int Urol Nephrol Sep López-Garibay LA, Cendejas-Gómez J de J, Rodríguez- Covarrubias F, Gómez-Conzatti A, Gabilondo-Navarro F, Sotomayor-de-Zavaleta M. [Long-term renal function in patients with renal-cell carcinoma treated surgically: comparison between radical and partial nephrectomy]. Rev Investig Clínica Organo Hosp Enfermedades Nutr Feb;65(1): Mariusdottir E, Jonsson E, Marteinsson VT, Sigurdsson MI, Gudbjartsson T. Kidney function following partial or radical nephrectomy for renal cell carcinoma: A population-based study. Scand J Urol Apr
Malta Medical Journal
MMJ Volume 26, Issue 3, 2014 Malta Medical Journal University of Malta Medical School http://www.um.edu.mt/umms/mmj Have you ever asked yourself how many viruses there are on earth? The answer is 10 31,
More informationRENAL CANCER GUIDELINES
Greater Manchester and Cheshire Cancer Network RENAL CANCER GUIDELINES Agreed by Urology CSG: July 2010 Review Date: July 2012 Renal Cancer Guidelines 1. Introduction 1.1 Kidney cancer accounts for 3%
More informationGUIDELINES ON RENAL CELL CARCINOMA
GUIDELINES ON RENAL CELL CARCINOMA B. Ljungberg (chairman), D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard, I.C. Sinescu Introduction This EAU guideline was prepared to help urologists
More informationGuidelines on Renal Cell
Guidelines on Renal Cell Carcinoma (Text update March 2009) B. Ljungberg (Chairman), D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard, I.C. Sinescu Introduction Renal cell carcinoma
More informationPROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH CHEMOTHERAPY
Journal of IMAB ISSN: 1312-773X http://www.journal-imab-bg.org http://dx.doi.org/10.5272/jimab.2016221.1045 Journal of IMAB - Annual Proceeding (Scientific Papers) 2016, vol. 22, issue 1 PROGNOSTIC FACTORS
More informationSurgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer
More informationComparison of Partial and Radical Nephrectomy for pt1b Renal Cell Carcinoma
www.kjurology.org DOI:10.4111/kju.2010.51.9.596 Urological Oncology Comparison of Partial and Radical Nephrectomy for pt1b Renal Cell Carcinoma Jong Min Kim, Phil Hyun Song, Hyun Tae Kim, Tong Choon Park
More informationLocal survival outcomes in metastatic renal cell carcinoma
Local survival outcomes in metastatic renal cell carcinoma Gerald Busuttil, Joseph Attard, David Farrugia, John Sciberras, Stephen Mattocks, Karl German, Patrick Zammit Abstract A quarter of patients who
More informationSt. Dominic s Annual Cancer Report Outcomes
St. Dominic s 2017 Annual Cancer Report Outcomes Cancer Program Practice Profile Reports (CP3R) St. Dominic s Cancer Committee monitors and ensures that patients treated at St. Dominic Hospital receive
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationGUIDELINES ON RENAL CELL CANCER
20 G. Mickisch (chairman), J. Carballido, S. Hellsten, H. Schulze, H. Mensink Eur Urol 2001;40(3):252-255 Introduction is characterised by a constant rise in incidence over the last 50 years, with a predominance
More informationTumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma
ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI
More informationPrognostic factors in localized renal cell cancer
Original Article PROGNOSTIC FACTORS IN LOCALIZED RENAL CELL CANCER KNIGHT and STADLER Prognostic factors in localized renal cell cancer David A. Knight and Walter M. Stadler Section of Hematology/Oncology,
More informationImpact of lymphadenectomy in management of renal cell carcinoma
Journal of the Egyptian National Cancer Institute (2012) 24, 57 61 Cairo University Journal of the Egyptian National Cancer Institute www.nci.cu.adu.eg www.sciencedirect.com ORIGINAL ARTICLE Impact of
More informationPatient Selection for Surgery in RCC with Thrombus. E. Jason Abel, M.D.
Patient Selection for Surgery in RCC with Thrombus E. Jason Abel, M.D. RCC with venous invasion Venous invasion occurs in ~10% of RCC Surgery more complex Increased risk for morbidity Thrombus may be confined
More informationRAPN. in T1b Renal Masses? A. Mottrie. G. Denaeyer, P. Schatteman, G. Novara
RAPN in T1b Renal Masses? A. Mottrie G. Denaeyer, P. Schatteman, G. Novara Department of Urology O.L.V. Clinic Aalst OLV Vattikuti Robotic Surgery Institute Aalst Belgium Guidelines on Renal Cell Carcinoma
More informationValidation of the 2009 TNM Classification for Renal Cell Carcinoma: Comparison with the 2002 TNM Classification by Concordance Index
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.8.524 Urological Oncology Validation of the 2009 TNM Classification for Renal Cell Carcinoma: Comparison with the 2002 TNM Classification by Concordance
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More informationLaparoscopic and Open Partial Nephrectomy: Complication Comparison Using the Clavien System
SCIENTIFIC PAPER Laparoscopic and Open Partial Nephrectomy: Complication Comparison Using the Clavien System Jennifer E. Reifsnyder, MD, Ranjith Ramasamy, MD, Casey K. Ng, MD, James DiPietro, BS, Benjamin
More informationManchester Cancer. Guidelines for the management of renal cancer
Guidelines for the management of renal cancer Approved by the urology pathway board September 2014 To be reviewed September 2016 Renal Cancer Guidelines 1. Introduction 1.1 Kidney cancer accounts for 3%
More informationComplex case Presentations
Complex case Presentations Case Presentations April 2016 Lisa M Pickering Case presentations: chromophobe renal carcinoma 60 year old man. ECOG PS 0 No significant comorbodities August 2009: L radical
More informationComplications in robotic surgery!! Review of the literature! RALP, RAPN and RARC!
Complications in robotic surgery Review of the literature RALP, RAPN and RARC Anna Wallerstedt, MD Karolinska University Hospital Stockholm, Sweden Agenda The importance of reporting surgical complications
More informationVincenzo Ficarra. Direttore Clinica di Urologia Azienda Ospedaliera Universitaria di Udine
Best Papers on Kidney Cancer Vincenzo Ficarra Direttore Clinica di Urologia Azienda Ospedaliera Universitaria di Udine Uro-oncological oncological topics Renal Tumor biopsy Positive Surgical Margins after
More informationThe Changing Evolution of Renal Tumours: A Single Center Experience over atwo-decade Period
European Urology European Urology 45 (2004) 490 494 The Changing Evolution of Renal Tumours: A Single Center Experience over atwo-decade Period Jean-Jacques Patard a,*, Hicham Tazi a, Karim Bensalah a,
More informationThe Role of Multitargeted Therapies in the Adjuvant Setting in Renal Cell Carcinoma
european urology supplements 7 (2008) 63 70 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Role of Multitargeted Therapies in the Adjuvant Setting in Renal Cell Carcinoma
More informationShould the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer
Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology
More informationEVALUATION OF THE OUTCOME OF THE MANAGEMENT OF PATIENTS WITH RENAL CELL CARCINOMA
International Invention Journal of Medicine and Medical Sciences (ISSN: 2408-7246) Vol. (9) pp. 99-204, November, 206 Available online http://internationalinventjournals.org/journals/iijmms Copyright 206
More informationSegmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter cancer
Int Urol Nephrol (2014) 46:921 926 DOI 10.1007/s11255-013-0514-z UROLOGY - ORIGINAL PAPER Segmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter
More informationGuidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationIs renal cryoablation becoming an effective alternative to partial nephrectomy?
Is renal cryoablation becoming an effective alternative to partial nephrectomy? J GARNON 1, G TSOUMAKIDOU 1, H LANG 2, A GANGI 1 1 department of interventional radiology 2 department of urology University
More informationComparison of Glomerular Filtration Rate (GFR) (RCC)
Merit Research Journal of Medicine and Medical Sciences (ISSN: 2354-323X) Vol. 3(10) pp. 467-471, October, 2015 Available online http://www.meritresearchjournals.org/mms/index.htm Copyright 2015 Merit
More informationWinship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients
Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD Assistant Professor, Genitourinary Medical Oncology Winship
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationIs There a Need to Further Subclassify pt2 Renal Cell Cancers as Implemented by the Revised 7th TNM Version?
EUROPEAN UROLOGY 59 (2011) 258 263 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Is There a Need to Further Subclassify pt2 Renal Cell Cancers as Implemented
More informationOncourology COMPLICATIONS OF PARTIAL NEPHRECTOMY AT OPERATIVE TREATMENT OF RENAL CELL CARCINOMA
1 Oncourology COMPLICATIONS OF PARTIAL NEPHRECTOMY AT OPERATIVE TREATMENT OF RENAL CELL CARCINOMA Address: Eduard Oleksandrovych Stakhovsky, 03022, Kyiv, Lomonosova Str., 33/43, National Cancer Institute
More informationPartial Nephrectomy Techniques for Renal Preservation: Historical and Modern Approaches
Partial Nephrectomy Techniques for Renal Preservation: Historical and Modern Approaches Cary N Robertson MD FACS Associate Professor Division of Urology Associate Director Urologic Oncology Duke Cancer
More informationSurgeons Perspective: LN as a Draining Pattern. Jose A. Karam, MD, FACS Associate Professor Department of Urology
Surgeons Perspective: LN as a Draining Pattern Jose A. Karam, MD, FACS Associate Professor Department of Urology Disclosures EMD Serono, Pfizer, Novartis: Advisory board/consultant Disclosures I perform
More informationSurgically Discovered Xanthogranulomatous Pyelonephritis Invading Inferior Vena Cava with Coexisting Renal Cell Carcinoma
Case Study TheScientificWorldJOURNAL (2009) 9, 5 9 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2009.6 Surgically Discovered Xanthogranulomatous Pyelonephritis Invading Inferior Vena Cava with Coexisting
More informationSurgical Management of Renal Cancer. David Nicol Consultant Urologist
Surgical Management of Renal Cancer David Nicol Consultant Urologist Roles of Surgery 1. Curative intervention localised disease 2. Symptomatic control advanced disease 3. Augmentation of efficacy of systemic
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationIndications For Partial
Indications For Partial Nephrectomy Christopher G. Wood, M. D., FACS Professor and Deputy Chairman Douglas E. Johnson, M. D. Endowed Professorship in Urology Department of Urology The University of Texas
More informationMultidisciplinary management of retroperitoneal sarcomas
Multidisciplinary management of retroperitoneal sarcomas Eric K. Nakakura, MD UCSF Department of Surgery UCSF Comprehensive Cancer Center San Francisco, CA 7 th Annual Clinical Cancer Update North Lake
More informationRadical Nephrectomy for Renal Cell Carcinoma Its Contemporary Role Related to Histologic Type, Tumor Size, and Nodal Status: A Retrospective Study
AJCP /ORIGINAL ARTICLE Radical Nephrectomy for Renal Cell Carcinoma Its Contemporary Role Related to Histologic Type, Tumor Size, and Nodal Status: A Retrospective Study Kamran M. Mirza, MD, PhD, Jerome
More informationUrinary Collecting System Invasion is an Independent Prognostic. Factor in Organ Confined Renal Cell Carcinomas.
Author manuscript, published in "Journal of Urology The 2009;182(3):854-9" DOI : 10.1016/j.juro.2009.05.017 Urinary Collecting System Invasion is an Independent Prognostic Factor in Organ Confined Renal
More informationPrognostic Factors and Staging Systems for Renal Cell Carcinoma
european urology supplements 6 (2007) 623 629 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors and Staging Systems for Renal Cell Carcinoma Vincenzo Ficarra
More informationHEPATECTOMY. Surgical Potpourri Session. ACS NSQIP National Conference Salt Lake City 2012
HEPATECTOMY Surgical Potpourri Session ACS NSQIP National Conference Salt Lake City 2012 Pascal Fuchshuber, MD, PhD, FACS Kaiser Permanente Medical Center Walnut Creek - California Hepatic Resection Is
More informationThe new TNM staging for renal cell carcinoma: what and why the urologists want to know.
The new TNM staging for renal cell carcinoma: what and why the urologists want to know. Poster No.: C-1132 Congress: ECR 2011 Type: Educational Exhibit Authors: Y. Y. Lim, A. Hattab, A. Bradley ; Manchester/UK,
More informationCASE REPORT. Introduction. Case series reports. J Thorac Dis 2012;4(S1): DOI: /j.issn s003
CASE REPORT Lost in time pulmonary metastases of renal cell carcinoma: complete surgical resection of metachronous metastases, 18 and 15 years after nephrectomy Kosmas Tsakiridis 1, Aikaterini N Visouli
More informationChallenges in RCC surgery. Treatment Goals. Surgical challenges. Management options in VHL associated RCCs
Management options in VHL associated RCCs Challenges in RCC surgery JJ PATARD, MD, PhD Paris XI University Observation, Radical nephrectomy, Renal parenchymal sparing surgery, Open, laparoscopic, robotic
More informationWho are Candidates for Laparoscopic or Open Radical Nephrectomy. Arieh Shalhav
Who are Candidates for Laparoscopic or Open Radical Nephrectomy Arieh Shalhav Fritz Duda Chair of Urologic Surgery Professor of Surgery and the Comprehensive Cancer Research Center Who are Candidates for
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationis time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the
My name is Barry Feig. I am a Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. I am going to talk to you today about the role for surgery in the treatment
More informationBone Metastases in Muscle-Invasive Bladder Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
More informationRenal Cell Cancer. Clinical case study 1 & 2. Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland
Renal Cell Cancer Clinical case study 1 & 2 Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland 1 Case study 1 - RCC and Lung Metastases Case study 1: Patient History Male, 63 years old Mild
More informationUpper urinary tract urothelial carcinomas (UTUC)
Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract Manel Mellouli 1 *, Slim Charfi 1, Walid Smaoui 2, Rim Kallel 1, Abdelmajid Khabir 1, Mehdi Bouacida
More informationReflections on the current knowledge of epidemiology, treatment and prognosis for renal cell carcinoma Hew, M.N.
UvA-DARE (Digital Academic Repository) Reflections on the current knowledge of epidemiology, treatment and prognosis for renal cell carcinoma Hew, M.N. Link to publication Citation for published version
More informationSustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma
JOURNAL OF CASE REPORTS 2015;5(1):280-284 Sustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma Chanchal Goswami, Aditi Mandal B. P. Poddar Hospital & Medical Research
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationCT PET SCANNING for GIT Malignancies A clinician s perspective
CT PET SCANNING for GIT Malignancies A clinician s perspective Damon Bizos Head, Surgical Gastroenterology Charlotte Maxeke Johannesburg Academic Hospital Case presentation 54 year old with recent onset
More informationComparison of Long-Term Results After Nephron-Sparing Surgery and Radical Nephrectomy in Treating 4- to 7-cm Renal Cell Carcinoma
:3-8 3 Comparison of Long-Term Results After Nephron-Sparing Surgery and Radical Nephrectomy in Treating 4- to 7-cm Renal Cell Carcinoma Daimantas Milonas, Giedrius Skulčius, Ruslanas Baltrimavičius, Stasys
More informationNCCN AND AUA GUIDELINES FOR RCC:
NCCN AND AUA GUIDELINES FOR RCC: DO THEY EFFECTIVELY CAPTURE RECURRENCES FOLLOWING NEPHRECTOMY? Suzanne B. Stewart, MD 1, R. Houston Thompson, MD 1, Sarah P. Psutka, MD 1, John C. Cheville, MD 2, Christine
More informationLymphadenectomy in RCC: Yes, No, Clinical Trial?
Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University
More informationManagement of High Risk Renal Cell Carcinoma
Management of High Risk Renal Cell Carcinoma Peter E. Clark, MD Professor and Chair, Department of Urology Carolinas HealthCare System Chair, Urologic Oncology Levine Cancer Institute October 14, 2017
More informationUreteroscopy Is Indicated in every patient with suspected Upper Tract Urothelial Tumor
Ureteroscopy Is Indicated in every patient with suspected Upper Tract Urothelial Tumor Scott G. Hubosky, MD The Demetrius H. Bagley Jr., MD Associate Professor of Urology Director of Endourology Vice Chair
More informationClinical Symptoms Predict Poor Overall Survival in Chronic-dialysis Patients with Renal Cell Carcinoma Associated with End-stage Renal Disease
Jpn J Clin Oncol 2014;44(11)1096 1100 doi:10.1093/jjco/hyu117 Advance Access Publication 19 August 2014 Clinical Symptoms Predict Poor Overall Survival in Chronic-dialysis Patients with Renal Cell Carcinoma
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationREAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO
REAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO Alain Ravaud, MD.PhD Bordeaux. France DISCLOSURES Consultant for: Pfizer, Novartis, GlaxoSmithKline, Roche, Bristol-Myers Squibb Institutional
More informationDiagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018
Diagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018 Dr. Tzahi Neuman Dep.Of Pathology Hadassah Medical Center Jerusalem, Israel, (tneuman@hadassah.org.il) Disclosure: 1 no conflicts of
More informationXiang Hu*, Liang Cao*, Yi Yu. Introduction
Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang
More informationBaker Alabbadi MD*, Ali Alasmar MD*, Ayman Alqarallah MD*, Nizar Saaydah MD* ABSTRACT
Renal Cell Carcinoma Clinical Presentation and Histopathological Findings: A Retrospective Analysis of a Jordanian Population at King Hussein Medical Center Baker Alabbadi MD*, Ali Alasmar MD*, Ayman Alqarallah
More informationPatient Selection for Ablative Therapies. Adrian D Joyce Leeds UK
Patient Selection for Ablative Adrian D Joyce Leeds UK Therapy Renal Cell Ca USA: 30,000 new cases annually >12,000 deaths RCC accounts for 3% of all adult malignancy 40% of patients will die from their
More informationPatient Reported Weight Loss Predicts Recurrence Rate in Renal Cell Cancer Cases after Nephrectomy
DOI:10.22034/APJCP.2018.19.4.891 RESEARCH ARTICLE Editorial Process: Submission:01/04/2017 Acceptance:09/11/2017 Patient Reported Weight Loss Predicts Recurrence Rate in Renal Cell Cancer Cases after Nephrectomy
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationCanadian Urological Association guidelines for followup of patients after treatment of nonmetastatic
Canadian Urological Association guidelines for followup of patients after treatment of nonmetastatic renal cell carcinoma Wassim Kassouf, Leonardo L. Monteiro, Darrel E. Drachenberg, Adrian S. Fairey,
More informationSolitary Contralateral Adrenal Metastases after Nephrectomy for Renal Cell Carcinoma
Original Report ISSN 1537-744X; DOI 10.1100/tsw.2004.39 Solitary Contralateral Adrenal after Nephrectomy for Renal Cell Carcinoma Nikolaos Antoniou, M.D. and Demetrios Karanastasis, M.D. General Hospital
More informationWhat is the role of partial nephrectomy in the context of active surveillance and renal ablation?
What is the role of partial nephrectomy in the context of active surveillance and renal ablation? Dogu Teber Department of Urology University Hospital Heidelberg Coming from Heidelberg obligates to speak
More informationOverall Survival and Development of Stage IV Chronic Kidney Disease in Patients Undergoing Partial and Radical Nephrectomy for Benign Renal Tumors
EUROPEAN UROLOGY 64 (2013) 600 606 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Kidney Cancer Editorial by Alexander Kutikov, Marc C. Smaldone and Robert
More informationTyrosine Kinase Inhibitors in Clinical Practice: Case Reports
european urology supplements 7 (2008) 610 614 available at www.sciencedirect.com journal homepage: www.europeanurology.com Tyrosine Kinase Inhibitors in Clinical Practice: Case Reports Vincenzo Ficarra
More informationDATA REPORT. August 2014
AUDIT DATA REPORT August 2014 Prepared for the Australian and New Zealand Gastric and Oesophageal Surgical Association by the Royal Australasian College of Surgeons 199 Ward St, North Adelaide, SA 5006
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters
Preoperative Neutrophil-to-Lymphocyte Ratio and Neutrophilia Are Independent Predictors of Recurrence in Patients with Localized Papillary Renal Cell Carcinoma The Harvard community has made this article
More informationNEPHRECTOMY AUDIT. OCTOBER 1998-SEPTEMBER 2005 Dr. Sanjeev Bandi MBBS., FRCSI., FRACS(Urology) Mater Misericordiae Hospital, Mackay, Qld 4740
NEPHRECTOMY AUDIT OCTOBER 1998-SEPTEMBER 2005 Dr. Sanjeev Bandi MBBS., FRCSI., FRACS(Urology) Mater Misericordiae Hospital, Mackay, Qld 4740 This audit has been performed in conjunction with the data requirements
More informationFinancial and Other Disclosures
Financial and Other Disclosures Off-label use of drugs, devices, or other agents: None Data from IRB-approved human research is not presented I have the following financial interests or relationships to
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationComparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population
DOI 10.1007/s10147-015-0812-9 ORIGINAL ARTICLE Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population Yasunobu
More informationTransitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as a Spinal Cord Compression
Case Study TheScientificWorldJOURNAL (2008) 8, 223 227 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2008.43 Transitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationWHAT IS THE ROLE OF ACTIVE SURVEILLANCE
WHAT IS THE ROLE OF ACTIVE SURVEILLANCE IN THE CONTEXT OF RENAL ABLATION AND PARTIAL NEPHRECTOMY? Alessandro Volpe University of Eastern Piedmont Novara, Italy RCC INCIDENCE SEER DATABASE (1975-2006) RCC
More information1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.
History and Physical Case Scenario 1 45 year old white male presents with complaints of nausea, weight loss, and back pain. A CT of the chest, abdomen and pelvis was done on 12/8/12 that revealed a 12
More informationLong-term Survival in Patients Undergoing Radical Nephrectomy and Inferior Vena Cava Thrombectomy: Single-Center Experience
EUROPEAN UROLOGY 57 (2010) 667 672 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Long-term Survival in Patients Undergoing Radical Nephrectomy and Inferior
More informationMetachronous anterior urethral metastasis of prostatic ductal adenocarcinoma
http://dx.doi.org/10.7180/kmj.2016.31.1.66 KMJ Case Report Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma Jeong Hyun Oh 1, Taek Sang Kim 1, Hyun Yul Rhew 1, Bong Kwon Chun
More informationOptimal Treatment of ct1b Renal Mass in Patient with Normal GFR: a Role for Radical Nephrectomy?
Optimal Treatment of ct1b Renal Mass in Patient with Normal GFR: a Role for Radical Nephrectomy? Steven C. Campbell, MD, PhD Program Director, Vice Chairman Department of Urology Center for Urologic Oncology
More informationRenal cell cancer: overview and immunochemotherapy
1 Renal cell cancer: overview and immunochemotherapy Vincent Khoo Introduction and epidemiology Kidney cancer is a relatively common urological cancer, accounting for approximately 2% of all adult cancers.
More informationRetroperitoneoscopic Radical Nephrectomy: Initial Experience
Retroperitoneoscopic Radical Nephrectomy: Initial Experience A. Hasegan 1, D. Bratu 2, V. Pirvut 1, I. Mihai 1, N. Grigore 1 1 Lucian Blaga University of Sibiu, Department of Urology 2 Lucian Blaga University
More informationPresentation of Cases /Audience Voting/Panel/Discussion
Presentation of Cases /Audience Voting/Panel/Discussion JJ Patard Tim O Brien Ninth European International Kidney Cancer Symposium Dublin 25-26 April 2014 Clinical case 1 63 years old women Medical past
More informationTransfusion & Mortality. Philippe Van der Linden MD, PhD
Transfusion & Mortality Philippe Van der Linden MD, PhD Conflict of Interest Disclosure In the past 5 years, I have received honoraria or travel support for consulting or lecturing from the following companies:
More informationSurgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 23 March 2012, Sao Paulo, Brazil Surgery of RCC Locally confined (small) renal tumours Locally advanced disease Metastatic
More informationFactors Affecting the Time to Recurrence After Radical Nephrectomy for Localized Renal Cell Carcinoma
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.11.744 Urological Oncology Factors Affecting the Time to Recurrence After Radical Nephrectomy for Localized Renal Cell Carcinoma Hee-Seo Son, Seung
More informationPresented By: Samik Patel MD. Martinovski M 1, Patel S 1, Navratil A 2, Zeni T 3, Jonker M 3, Ferraro J 1, Albright J 1, Cleary RK 1
Effects of Resident or Fellow Participation in Sleeve Gastrectomy and Gastric Bypass: Results from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) Martinovski
More information